{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.3","upperLimit":"95.7","value":"67"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"81.6","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the IMWG Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR \\>= 90% reduction in serum M-component plus urine M-component \\<100 mg/24 h; PR = \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation"},{"description":"Participants were administered 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG001","title":"Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 1 - Percentage of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}